fluticasone furoate/vilanterol vs Fluticasone propionate/salmeterol (Advair Diskus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01313676 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 16,568 participants, with all-cause mortality as an objective clinical primary endpoint. However, the fluticasone furoate/vilanterol versus placebo comparison did not meet statistical significance (hazard ratio 0.878, p=0.137), and the record does not report a power calculation.

Reported efficacy

Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants (missed)

Result source: NCT01313676

Fluticasone propionate/salmeterol (Advair Diskus)

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​vilanterolFluticasone propionate/​salmeterol (Advair Diskus)
Moderate or severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
SGRQ total, change—Not reported—Not reported
TDI focal score—Not reported—Not reported

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​vilanterol
—Not reported
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not reported

Trough FEV1, change

fluticasone furoate/​vilanterol
—Not reported
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not reported

SGRQ total, change

fluticasone furoate/​vilanterol
—Not reported
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not reported

TDI focal score

fluticasone furoate/​vilanterol
—Not reported
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Fluticasone propionate/salmeterol (Advair Diskus): registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

fluticasone furoate/vilanterol
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants NCT01313676 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Asthma

Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT01086384 · Phase 3 · completed

This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.

Reported efficacy

Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)

Result source: NCT01086384

Fluticasone propionate/salmeterol (Advair Diskus)

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Partial signal

NCT00920959 · Phase 3 · completed

This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)

Result source: NCT00920959

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​vilanterolFluticasone propionate/​salmeterol (Advair Diskus)
Severe exacerbations, annualised rate—Trial running · NCT057571022.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT00452348
Trough FEV1, change0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
ACQ-5, change-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
—Not posted · NCT00920959
OCS dose reduction—Trial running · NCT05757102—Not posted · NCT00920959

Severe exacerbations, annualised rate

fluticasone furoate/​vilanterol
—Trial running · NCT05757102
Fluticasone propionate/​salmeterol (Advair Diskus)
2.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT00452348

Trough FEV1, change

fluticasone furoate/​vilanterol
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
Fluticasone propionate/​salmeterol (Advair Diskus)
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348

ACQ-5, change

fluticasone furoate/​vilanterol
-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959

OCS dose reduction

fluticasone furoate/​vilanterol
—Trial running · NCT05757102
Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. fluticasone furoate/vilanterol: 12 of 12 rows · Fluticasone propionate/salmeterol (Advair Diskus): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​vilanterol
Rows use multiple source trials
Fluticasone propionate/​salmeterol (Advair Diskus)
Rows use multiple source trials
ACT Control
responder rate · % of participants
92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
ACT Total
absolute change · score
4.4 vs 2.5 placebo score @ 12wk100/25 µg ODa,b
NCT01165138 · Phase 3
5.4 vs 4.5 placebo score @ 12wk50/12.5 mcg BIDa,b
NCT02980133 · Phase 3 · registry result, not featured evidence
AM PEF Change L/Min
absolute change · L/min
8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
Evening PEF
absolute change · L/min
26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODc,a,b,d
NCT01165138 · Phase 3
2 other source trials
39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3
41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD
NCT01686633 · Phase 3
10.8 vs 7.6 FP L/min @ 4wk100/50mcg BIDc,a,b,d
NCT00118716 · Phase 4 · registry result, not featured evidence
Evening PEF Change L/Min
absolute change · L/min
5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
FEV1
absolute change · L
0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b
NCT02301975 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b
NCT02301975 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period
percent change · % of baseline
-3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
-3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
Symptom-free 24 h Periods
absolute change · percentage points
-3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
-3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b
NCT02301975 · Phase 3 · registry result, not featured evidence
Dropout rate
—100/25 µgf
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
7.2%200/25 µg OD
NCT01686633 · Phase 3
9.2%100/25 µg OD
NCT01686633 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
14.4%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
12.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
0.2%g
NCT01475721 · Phase 4
show 14 more results
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
7.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
Discontinued due to AEs
—100/25 µgf
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
0.9%200/25 µg OD
NCT01686633 · Phase 3
0.9%100/25 µg OD
NCT01686633 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
2.6%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
1.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—g
NCT01475721 · Phase 4
show 14 more results
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
0.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
Serious AEs
4.1%100/25 µgf
NCT01086384 · Phase 3
show 16 more results
0.5%200/25 µg OD
NCT01018186 · Phase 3
1.5%100/25 µg OD
NCT01018186 · Phase 3
1.1%
NCT03248128 · Phase 3 · Asthma · phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
0.3%200/25 µg OD
NCT01686633 · Phase 3
1.2%100/25 µg OD
NCT01686633 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1%100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
1.4%100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
1.3%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.6%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
2.3%g
NCT01475721 · Phase 4
show 14 more results
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
4.4%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0%100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
0%
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
Most frequent reported AEs
100/25 µgf
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3
show 15 more results
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3
nasopharyngitis 10.4%
upper respiratory tract infection 7%
rhinitis allergic 4.2%
NCT03248128 · Phase 3 · Asthma · phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100/25 µg OD
nasopharyngitis 11.4%
headache 8.4%
upper respiratory tract infection 6.2%
NCT01147848 · Phase 3 · Asthma · phase 3
100/25 µg QD
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
100/25 µg Once Daily
upper respiratory tract infection 7.2% (placebo 9.1%)
headache 4.6% (placebo 1.9%)
nasopharyngitis 4.6% (placebo 8.4%)
NCT01498679 · Phase 3 · registry result, not featured evidence
200/25 µg Once Daily
upper respiratory tract infection 8.4%
nasopharyngitis 3.9%
rhinitis allergic 3.2%
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence
g
asthma 0.8%
NCT01475721 · Phase 4
show 14 more results
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/31.25/25 mcg
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
250/50 mcg BID
headache 11%
hypertension 6.1%
blood pressure increased 0%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
250/50 mcg BID
headache 12.2%
hypertension 4.9%
blood pressure increased 3.7%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100mcg/50mcg
cough 5%
upper respiratory infection 5%
viral upper respiratory infection 5%
NCT00927758 · Phase 2 · registry result, not featured evidence
headache 5.6% (placebo 5.4%)
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cTrial phases differ: Phase 3 versus Phase 4.
  4. dAssessment timepoints differ: 12 weeks versus 4 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for 13 of these studies.
  7. gPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/vilanterol

Severe Exacerbation Occurrence 15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk100/25 µg
event count · % of participants
NCT01086384 · Phase 3 · converted to % from 154 participants as posted
Severe Exacerbation Rate Annualized 200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µg
event rate · Severe asthma exacerbations
NCT01086384 · Phase 3
FEV1 Weighted Mean 0-4h 2.082 vs 1.994 FF L @ 12wk
absolute value · L
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
1.762 vs 1.711 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Morning PEF 47.7 vs 19.1 FF L/min @ 12wk200/25 µg OD
absolute change · L/min
NCT01686633 · Phase 3
show 6 more results
46.2 vs 14 Fluticasone Propionate L/min200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
32.9 vs -0.4 placebo L/min @ 12wk100/25 µg OD
NCT01165138 · Phase 3
44.3 vs 19.1 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3
43.6 vs -9.3 placebo L/min @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
11.9 vs 8.9 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
14.9 vs 9.3 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Rescue-free 24-h Period 25.9% (n=453) vs 25.8% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.3% (n=336) vs 25.6% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Symptom-free 24-h Period 25.7% (n=453) vs 24.6% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.2% (n=336) vs 25.8% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
ACQ-5 -1.21 vs -1.09 FF score @ 24wk
absolute change · score
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
-1.25 vs -1.13 FF score @ 24wk
NCT03248128 · Phase 3 · Asthma · phase 3
FEV1 Wm0 24 h 0.499 vs 0.366 FF L @ 12wk200/25 µg OD
absolute change · L
NCT01686633 · Phase 3
show 3 more results
0.513 vs 0.212 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.474 vs 0.366 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Symptom-free 24-h Period 29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD
percent change · % of baseline
NCT01686633 · Phase 3
show 3 more results
32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg OD
NCT01165138 · Phase 3
27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
AQLQ Total 0.8 vs 0.69 Fluticasone Propionate score @ 12wk200/25 µg Once Daily
absolute change · score
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
show 4 more results
0.91 vs 0.61 placebo score @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.84 vs 0.33 placebo score @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.74 vs 0.66 FF score @ 12wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough 2.83 vs 2.462 placebo L @ 12wk100/25 µg OD
absolute value · L
NCT01165138 · Phase 3
Rescue-free 24-h Period 38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD
absolute change · percentage points
Rescue-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3

+ 10 further endpoints in the CSV export.

Fluticasone propionate/salmeterol (Advair Diskus)

Asthma Exacerbation Occurrence 8.2% (n=5834) vs 10.2% (n=5845) Fluticasone Propionate @ 26wk
event count · % of participants
NCT01475721 · Phase 4 · converted to % from 480 Participants as posted
Morning PEF 27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
absolute change · L
NCT00452348 · Phase 4 · registry result, not featured evidence
show 2 more results
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 2.63 vs 2.73 FP DISKUS per year @ 52wk250/50 mcg BID
event rate · per year
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 Max Fall -9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BID
absolute value · percentage points
NCT00118716 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence
Rescue-free 59.4 vs 54.7 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
Asthma Symptom Free 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
PAQLQ 0.49 vs 0.52 FP score @ 2wk100/50mcg BID
absolute change · score
Overall score Week 2
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Fluticasone propionate/salmeterol (Advair Diskus)'s landscape